Sarepta More than Doubles on Promising Study of Muscular Dystrophy Treatment

Sarepta

surged more than 140 percent Tuesday morning on news that its treatment of Duchenne Muscular Dystrophy showed significant clinical benefit in a study. "The magnitude of this clinical benefit is an unprecedented treatment effect in DMD. This result represents a major advance in the pursuit of a disease modifying treatment for this severe, progressive and life-threatening disease," said Jerry Mendell, M.D., Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investigator of the Phase IIb study. Sarepta is now trading at $8.41, an increase of 143.06 percent. Shares are still short of their six-month high of $9.60, achieved in late March.